Dr. Reddy’s re-appoints G V Prasad as Co-Chairman and Managing Director

Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation

Sigachi Industries begins disbursing Interim ex-gratia to families of deceased

Laurus Labs to invest €5 million in JV KRKA Pharma

The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility

Laurus Labs consolidated Q1 FY2026 PAT at Rs. 163.02 Cr

Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025

Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr

Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025

Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr

Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025

RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr

RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore

48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India